Tyrosine kinase inhibitor prodrug-loaded liposomes for controlled release at tumor microenvironment

Salmaso, Stefano; Mastrotto, Francesca; Roverso, Marco; Gandin, Valentina; Frión-Herrera, Yahima; Gabbia, Daniela; Franco, Michele De; Vaccarin, Christian; Verona, Marco; Chilin, Adriana; Caliceti, Paolo; Bogialli, Sara; Marzaro, Giovanni

doi:10.1016/j.jconrel.2021.11.006

Cited by 11 publications

(5 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TKIs are also reported to be substrates for cytochrome P450 enzymes. Their metabolites are more hydrophilic and may have less kinase selectivity and more off-target interactions than the parent drug [ 74 , 75 ]. Therefore, understanding the pharmacokinetics and pharmacodynamics of TKIs in the brain is also essential for their future applications in GBM [ 14 ].…”

Section: Clinical Trials Of Tkis In Treatment Of Gbm and Disappointin...mentioning

confidence: 99%

“…These receptors include transferrin receptor, low-density lipoprotein receptor, low-density lipoprotein receptor-related protein, folate receptor, lactoferrin receptor, insulin receptor, diphtheria toxin receptor, neonatal Fc receptor, nicotinic acetylcholine receptor, nucleolin receptor, scavenger receptor class B type, and leptin receptor [ 141 ]. Drug release can also be modulated by additional approaches such as pH dependent release to achieve better effects [ 74 ].…”

Section: Strategies To Achieve Targeted Delivery Of Tkismentioning

confidence: 99%

See 1 more Smart Citation

Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery

Brar

Jose

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is an aggressive brain tumor with high mortality rates. Due to its invasiveness, heterogeneity, and incomplete resection, the treatment is very challenging. Targeted therapies such as tyrosine kinase inhibitors (TKIs) have great potential for GBM treatment, however, their efficacy is primarily limited by poor brain distribution due to the presence of the blood–brain barrier (BBB). This review focuses on the potential of TKIs in GBM therapy and provides an insight into the reasons behind unsuccessful clinical trials of TKIs in GBM despite the success in treating other cancer types. The main section is dedicated to the use of promising drug delivery strategies for targeted delivery to brain tumors. Use of brain targeted delivery strategies can help enhance the efficacy of TKIs in GBM. Among various drug delivery approaches used to bypass or cross BBB, utilizing nanocarriers is a promising strategy to augment the pharmacokinetic properties of TKIs and overcome their limitations. This is because of their advantages such as the ability to cross BBB, chemical stabilization of drug in circulation, passive or active targeting of tumor, modulation of drug release from the carrier, and the possibility to be delivered via non-invasive intranasal route.

show abstract

Section: Clinical Trials Of Tkis In Treatment Of Gbm and Disappointin...mentioning

confidence: 99%

Section: Strategies To Achieve Targeted Delivery Of Tkismentioning

confidence: 99%

Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery

Brar

Jose

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Combining the two types of drugs poses a unique challenge because the expected targets differ; the drug should be released into the bloodstream for anti-parasitic action in the erythrocytic phase while remaining stable enough to reach the hepatocytic phase of therapy. Thus, the model for drug loading presents a challenge but can be addressed by improving stability, either through the use of a trapping agent like polyglycolide polymer ( Miatmoko et al, 2017 ) or by employing a prodrug model encapsulated in a liposome ( Salmaso et al, 2021 ). On the other hand, Erythrocytic targeting is suitable for drugs with excellent permeability that can be slowly released with a membrane system whose fluidity is carefully regulated ( J. L. Liu et al, 2020 ).…”

Section: Liposome Modification For Antimalarial Drug Deliverymentioning

confidence: 99%

Advancing liposome technology for innovative strategies against malaria

Miatmoko,

Octavia,

Araki

et al. 2024

Saudi Pharmaceutical Journal

View full text Add to dashboard Cite

“…TKIs are widely studied for prodrug formulation. 111 Li et al synthesized a redox-sensitive prodrug polymers poly(oligo(ethylene glycol) methacrylate) (POEG)- b -PSSDas and a redox-insensitive POEG- b -PCCDas that comprise POEG hydrophilic blocks and oncogenic TKI dasatinib (DAS, the inhibitor of Src/Bcr-Abl)-conjugated hydrophobic blocks to form mixed micelles with DOX. The system substantially enhanced the solubility of DAS and facilitated the intravenous delivery of DAS.…”

Section: Prodrug-based Nano-dds Approaches For Anticancer Therapiesmentioning

confidence: 99%

Recent advances in engineering prodrug-based nanomedicines for cancer therapy

Shi,

Lin,

Zhou

et al. 2024

Mater. Adv.

View full text Add to dashboard Cite

show abstract

Tyrosine kinase inhibitor prodrug-loaded liposomes for controlled release at tumor microenvironment

Cited by 11 publications

References 46 publications

Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery

Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery

Advancing liposome technology for innovative strategies against malaria

Recent advances in engineering prodrug-based nanomedicines for cancer therapy

Contact Info

Product

Resources

About